How systematic discovery surfaces the market segment your business plan didn't know existed
Every disruptive technology company starts with a story about its market. The story is usually plausible, sometimes elegant, and almost always wrong in at least one important detail. The detail that gets wrong, more often than not, is the identity of the first customer. Founders tend to look at the largest available market, identify the most obvious end-buyer in that market, and assume that this is where the launch should be aimed. Then they spend two years discovering that the obvious buyer is not actually ready, and the real first customer is somewhere they were not looking.
This pattern is so reliable that the Sell Now™ Sales Playbook treats the discovery of the actual beachhead market as one of the central pre-launch activities. The market entry point — the specific customer profile and the specific problem they are urgently trying to solve — is usually not where the business plan said it would be. Finding it requires systematic discovery, and the answer is often in a place no one was looking.
Your business plan describes the market you imagined. The Sell NowTM Method describes the market that exists. They are not the same market.
Diagnostic Biochips went into market discovery for their new SomaFoucus electrophysiology instrument with a clear hypothesis. The end market was pharma drug discovery. The first customers would be pharmaceutical company discovery groups working on central nervous system therapies. This hypothesis was reasonable. The largest commercial opportunity for the technology genuinely is in pharma. The team had a real partnership with Merck that suggested the market was reachable. The path was, in theory, straightforward.
The discovery work told a different story. After dozens of conversations across pharma, the team confirmed that Merck was an outlier. The rest of the industry was interested in brain organoids, conceptually, but was not ready to deploy a screening tool. The repeated answer, when the team asked “what would get you there?”, was a pattern: pharma needed to see scientific evidence — peer-reviewed publications, validated assays, established protocols — before they would invest in tooling. They needed a body of translational research to exist first. And critically, they were not going to fund the creation of that body of research themselves.
The discovery process produced an unexpected finding. Sitting between pure academic basic-science research on one side and pharma drug discovery on the other, there was a third category of customer that the team had not initially seen. These were translational research groups — academic labs with explicit translational mandates, nonprofit research institutes like the Lieber Institute and Scripps, disease-focused foundations and centers, and university programs structured around drug development rather than basic science. They were doing exactly the work that pharma needed to see done. They were ready to buy now. They were the beachhead.
There is a structural reason these intermediate segments get overlooked. The largest commercial market — pharma, in this case — is the one investors ask about and business plans focus on. The basic research market is often the founder's home segment and feels too academic to anchor a commercial business. The middle market sits in a blind spot: not big enough to satisfy a Series A pitch, not familiar enough to match anyone's mental model, and often composed of buyers from multiple institution types — academic, nonprofit, foundation, government — who do not appear together in any single industry analysis.
And yet the middle market is frequently the ideal place to launch a disruptive product. Several characteristics tend to make these segments unusually attractive for early-stage commercial activity. The buyers are often technically sophisticated and willing to engage with imperfect early products. They have shorter purchasing cycles than enterprise buyers. They have higher tolerance for novel technology. And they are usually well-networked within their specialty, which means a single satisfied customer can produce multiple referrals.
DBC saw all of these dynamics in the translational research segment. The labs were small enough to make purchasing decisions quickly. They were sophisticated enough to engage with a beta product. They were generating exactly the kind of publication-track scientific work that would eventually validate the technology for pharma. And they knew each other. Cross-referrals became one of the most reliable lead-gen channels for the company, with one engaged customer regularly producing introductions to two or three more.
The discovery work that surfaces a middle market does not look fundamentally different from any other customer discovery. It is structured, hypothesis-driven, conducted in one-on-one conversations with potential buyers, and oriented around the question of what problem they are urgently trying to solve. What differs is the willingness to follow the data when it leads somewhere unexpected.
Two specific discovery questions tend to surface middle-market segments. The first is the question DBC kept asking pharma: “what would get you there?” When the obvious end buyer is not ready, the answer to this question often points directly at the buyer who is. The second question is the inverse: “who is doing this work today, even if they're not the buyer we expected?” Following both questions tends to reveal the segment that is already trying to solve the problem you are addressing, even if it is not the segment your business plan named.
There is one more pattern worth naming. Founders frequently dismiss middle-market segments as “too small” or “too niche” to be worth pursuing. This is almost always premature. A small, well-defined, high-intent segment that you can reach efficiently and serve completely is a more valuable launch market than a large, diffuse, uncertain segment that you cannot. Beachhead markets exist precisely to be small. They are the place from which you launch the larger campaign, not the place you stay forever.
In DBC's case, the translational research market that initially looked like a detour became the foundation everything else has been built on. The publications and case studies generated from that segment are now the proof points pharma asked for. Early customers have become reference accounts and sources of cross-referrals. The repeatable sales process developed in this segment is what will scale. And the path back to pharma is now clear, because the conditions pharma required to engage are being created by the customers DBC actually serves today.
The market your plan describes might be the market you eventually win. The market you actually launch into is almost always somewhere else. Find it first.
Based on the Sell Now™ Sales Playbook for (Disruptive) Product Launch and the LinkedIn Live conversation between Chris Morrison and Brian Jamison, CEO of Diagnostic Biochips.